Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024 10:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024 12:00 ET
|
Aptose Biosciences, Inc.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Second Quarter 2023
August 10, 2023 16:02 ET
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Aptose Reports Results for the First Quarter 2023
May 08, 2023 16:01 ET
|
Aptose Biosciences, Inc.
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet...
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...